CYP3A4 and CYP3A5 genetic polymorphisms and risk of prostate Cancer

Abstract

Prostate Cancer (PCa) has been the most common cancer in the world for several decades, and by 2008, there were an estimated 899,000 new cases representing 13.7% of the total. Nearly three-quarters i.e. 71.6% cases occur in developed countries whereas 28.4% cases occur in less developed countries. Worldwide, prostate cancer ranks third in cancer incidence and sixth in cancer mortality among men. Incidence rates of prostate cancer varies more than twenty-fold worldwide. The CYP3A4 and CYP3A5 genetic polymorphisms on susceptibility to prostate cancer have received particular interest since these enzymes play a central role in detoxification of major classes of carcinogens, free radicals, xenobiotics and cytotoxic drugs. In the current study we investigated the role of CYP3A4 and CYP3A5 polymorphisms as a genetic modifier of risk for individuals with prostate cancer as susceptible genotypes in Bangladeshi population.